Gyros AB announces first commercial application: Gyrolab™ MALDI.

26-Mar-2002

Gyros AB today announced the introduction of Gyrolab™ MALDI SP1 and Gyrolab Workstation, the company’s first products based on its proprietary Gyros™ microfluidic technology platform.

Gyrolab MALDI offers a unique, fully integrated process for sample preparation prior to MALDI mass spectrometry, an essential technique frequently used for protein identification in proteomics. This new approach to sample preparation gives those working in drug discovery a significant opportunity to increase the success rate of protein identification, particularly when working with low abundant proteins.

Gyrolab MALDI SP1, a microlaboratory in the form of a compact disk (CD), concentrates and purifies protein digests that are used for identification and crystallizes them directly onto MALDI target areas on the CD. Gyrolab Workstation controls the entire process, transferring samples and reagents into the microlaboratory and driving samples through every step of the application by spinning the CD. Each Gyrolab MALDI processes 96 samples simultaneously, after which the microlaboratory is transferred to a MALDI mass spectrometer for sample analysis and identification.

From April onwards the products will be presented at a number of key conferences and seminars in the US and Europe. Shipments are anticipated to begin mid-year.

“Excellent sample preparation is a crucial step towards achieving high sensitivity MS analysis and successful protein identification” explained Per Sjöberg, Executive Vice President Commercial Operations at Gyros AB, “There is a well-recognized demand for a reliable solution that can reproducibly prepare large numbers of samples and facilitate identification of low abundant proteins. Building from our technology platform we have integrated key steps into one streamlined run performed at nanoliter scale. We ensure that samples can be analyzed at sensitivity levels close to the detection limit of today’s MALDI mass spectrometers.”

“Many attempts have been made to automate sample preparation, but compromises have often been implemented between high sensitivity and saving time or resources,” added Maris Hartmanis, President and CEO, “This application is an example of the use of our proprietary technology platform for applications that can truly benefit from miniaturization and integration. Gyrolab MALDI is the first of many application-specific CDs that we are developing and Gyrolab Workstation is a flexible instrument platform that can be readily adapted to new applications. We are extremely pleased with our rapid development, after only two years as an independent company”.


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.